Injectable quinolones
Abstract
Fluoroquinolones have been used worldwide against a variety of infections because of their potent antibacterial activity and good pharmacokinetics. In Europe and USA, ciprofloxacin and levofloxacin showed a good therapeutic efficacy for the past decade by sequential therapy for infections caused by Gram-negative bacteria including Pseudomonas aeruginosa and Gram-positive pathogens including penicillin-resistant Streptococcus pneumoniae. Recently, injection form of ciprofloxacin was launched in Japan, and pazufloxacin, gatifloxacin, and sitafloxacin are under development. Appropriate usage of these injectable quinolones in Japanese medical practice should be established from the potency of each drug, the surveillance data of drug-resistance, and the experience in Europe and USA.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.